EUVIMEDEUVIMED entdecken
BeobachtungsstudieFall-Kontroll-StudieOpen Access · CC BY-NC-ND 4.0

Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study

Bing Wang, Lynne Giles iD, Prabha Andraweera iD, Mark McMillan iD, Rebecca Beazley, Sara Almond, Noel Lally, Charlotte Bell, Louise Flood iD, James Ward, Helen Marshall

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf372 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Bing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Meningococcal Vaccines, Gonorrhea, Meningococcal Infections, Vaccine Efficacy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A publicly funded 4CMenB program has been implemented in South Australia since 2018. We aimed to evaluate vaccine effectiveness (VE) and vaccine impact on invasive meningococcal B (MenB) disease and gonococcal infections 5 years after the program introduction.

Methods

Vaccine impact was assessed using a Poisson or negative binomial regression model, and VE was estimated using both cohort screening and case-control methods. VE against the subsequent gonococcal infection was measured using a Cox regression model.

Results

Relative reductions of 72.7% (95% confidence interval [CI], 38.0%–88.0%) and 76.2% (41.6%–90.3%) in the incidence of MenB disease were observed in infants aged <1 year and adolescents aged 15–18 years, respectively. VE against MenB disease for the 3-dose schedule was 98.5% (95% CI, 81.9%–99.9%) in children and 92.3% (34.3%–99.1%) for the 2-dose vaccination in adolescents. VE for 2-dose vaccination against gonococcal infections in adolescents was 39.1% (95% CI, 31.3%–46.0%). Lower VE estimates were demonstrated in those >5 years compared to within 5 years since vaccination (−6.3% (95% CI, −44.5% to 21.8%) vs 41.8% (34.0%–48.7%). The VE against the subsequent gonococcal infection was 27.0% (adjusted hazard ratio, 0.730 [95% CI, .540–.988]), comparing fully vaccinated with unvaccinated case patients.

Conclusions

4CMenB demonstrates high protection against MenB disease in children and adolescents at 5 years. Moderate protection against the first and subsequent gonococcal infections in adolescents was observed up to 5 years after vaccination, with waning evident after 5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal VaccinesGonorrheaMeningococcal InfectionsVaccine EfficacyImmunization ProgramsNeisseria meningitidis, Serogroup BHumansAdolescentFemaleSouth AustraliaMaleInfantChild, PreschoolChildCase-Control StudiesCohort StudiesVaccinationIncidenceNeisseria gonorrhoeae

Stichwörter der Autor:innen

4CMenBMenB vaccinegonococcal and meningococcal infectionsvaccine effectivenessvaccine impact

Substanzen

Meningococcal Vaccines4CMenB vaccine

Autor:innen und Institutionen

  • Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.
  • Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
  • School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia.
  • Communicable Disease Control Branch, SA Health, Adelaide, South Australia, Australia.
  • UQ Poche Centre for Indigenous Health, University of Queensland, Brisbane, Queensland, Australia.

ORCID-Profile: Lynne Giles, Prabha Andraweera, Mark McMillan, Louise Flood

Zitieren

APA

Wang, B., Giles, L., Andraweera, P., McMillan, M., Beazley, R., Almond, S., Lally, N., Bell, C., Flood, L., Ward, J., & Marshall, H. (2025). Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf372

Vancouver

Wang B, Giles L, Andraweera P, McMillan M, Beazley R, Almond S, et al. Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf372

BibTeX
@article{Wang2025,
  author = {Wang, Bing and Giles, Lynne and Andraweera, Prabha and McMillan, Mark and Beazley, Rebecca and Almond, Sara and Lally, Noel and Bell, Charlotte and Flood, Louise and Ward, James and Marshall, Helen},
  title = {Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf372}
}
Kostenlos starten →